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Stage groupingAbstract Aim: We investigated the effect of the new tumour-, node-, metastasis- (TNM) clas-
siﬁcation on predicting and discriminating gastric cancer patient prognosis using the National
Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) Program.
Patients and methods: From the SEER-database we retrieved gastric cancer patients with a
primary adenocarcinoma, of Caucasian or Asian ethnicity and without distant metastases
(M0). The pTNM-stage was determined according to the 7th edition of the union internatio-
nale contre le cancer (UICC) guidelines.
Results: Spanning the period 2004–2010, 6136 patients fulﬁlled all inclusion criteria including
3424 (55.8%) men, 2712 (44.2%) women, 4629 (75.4%) Caucasian and 1507 (24.6%) Asian
patients. 1524 (24.8%) patients underwent total gastrectomy and 4612 (75.2%) non-total gas-
trectomy. Only in 41.2% of the patients were >15 lymph nodes resected. 1857 (31.0%) patients
received radiotherapy. Patient survival depended on ethnicity, type of surgery and radiother-
apy. The discriminating value of the UICC-stage grouping could not be validated for Cauca-
sian patients with >15 lymph nodes resected and who had not received radiotherapy: stage
groups IIB, IIIA, IIIB and IIIC showed substantial overlap in survival ranges. In addition,
the tumour speciﬁc survival of the different T-/N-combinations was signiﬁcantly different
in stage groups IIIB and IIIC, respectively.
Conclusions: Our retrospective analysis of the SEER-database does not validate the discrim-
inating value of stage grouping of the 7th edition of the UICC-stage grouping. A revision
should be considered and more reliable prognostic biomarkers are urgently needed.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).rmany.
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Gastric cancer (GC) is the second leading cause of
cancer related deaths in men and women [1,2]. The vast
majority of GC patients are diagnosed with advanced
stage disease with lymph node metastases already pres-
ent, leading to poor prognosis [3–6]. Treatment options
in patients with advanced GC are limited, but perioper-
ative, adjuvant as well as palliative chemotherapy
improve progression free and overall survival [7–10].
With regard to prognostic biomarkers, only the
tumour- (T), node- (N), metastasis (M)-classiﬁcation of
the union internationale contre le cancer (UICC) is cur-
rently used on a routine basis. It is the most important
instrument for tailoring oncologic treatment of cancer
patients. Generally, the TNM-classiﬁcation has stood
the test of time and was never surpassed in multivariate
analyses by another single prognostic biomarker, such
as immunohistochemistry or RNA/DNA-based tests.
The TNM-classiﬁcation is used in clinical trials to select
patients who are eligible for inclusion and in cancer regis-
tries to compare outcome between diﬀerent series, across
diﬀerent countries, over diﬀerent time periods (i.e. ethnic-
ity, medical treatment developments, socio-cultural
eﬀects) and particularly between diﬀerent studies. Thus,
changes in the TNM-classiﬁcation have many implica-
tions and eﬀect directly cancer care patients receive.
A few years ago, the UICC published the 7th edition
of the TNM classiﬁcation, introducing many changes
for GC [11]. Since then many studies aimed to validate
the prognostic value of the new TNM-classiﬁcation sys-
tem for GC [12–21], particularly of the new stage group-
ing. Twice as many studies were carried out on Asian
populations [12–15,17,19,20] than on Western popula-
tions [16,18,21]. However, concern arose whether the
new stage grouping of GC is appropriate and clinically
useful [16,20,21]. Particularly, 32–65% of GC patients
underwent stage migration from the 6th to the 7th edi-
tion of the TNM-classiﬁcation scheme [14,21]. This
raises concerns and in order to justify this substantial
‘patient migration’ among stage groups, stage grouping
was either unnecessary for clinical purposes or it did not
adequately reﬂect prognostic subgroups and needed
urgent revision. What was the evidence for changing
stage grouping and is the current TNM-classiﬁcation
more appropriate for the prediction of GC prognosis?
Unfortunately, and diﬀerent from national treatment
guidelines [22,23], categories of evidence and consensus
are not provided for the TNM-classiﬁcation and deci-
sion processes are not publicised.
In view of the overwhelming number of Asian study
cohorts and the paucity of Western study populations,
we asked ourselves whether the Surveillance, Epidemiol-
ogy and End Results (SEER)-database validates the
prognostic and discriminating value of the novel UICC-
stage grouping of GC and whether it may help to identifytreatment eﬀects on patient survival, which need to be
considered, when the prognostic and discriminating
value of the UICC-stage grouping of GC is validated.
2. Materials and methods
2.1. Patients
The National Cancer Institute’s Surveillance, Epide-
miology and End Results (SEER) Program registries
are among the most accurate and complete popula-
tion-based cancer registries in the world. The SEER
Program is comprised of 18 cancer registries across the
United States, including state, central, metropolitan
and the Alaska Native registries. Together, they gather
data from approximately 28% of the U.S. population
(http://seer.cancer.gov/). From the SEER database we
retrieved GC patients using the following inclusion
and exclusion criteria (Suppl. Table 1). Patients were
included when the primary tumour localisation was
the stomach (C16.1 through C16.9), the patient was
aged P18 years, the patient was of Caucasian or Asian
ethnicity (Chinese, Japanese, Korean or Vietnamese),
histology had conﬁrmed an adenocarcinoma (ICD-0-
3M-8140/3, M-8142/3 through M-8145/3, M-8210/3,
M-8211/3, M-8255/3, M-8260/3 through M-8263/3,
M-8310/3, M-8323/3, M-8480/3, M-8481/3, M-8490/
3). Patients were excluded when distant metastases were
apparent (M1), histology identiﬁed a tumour type other
than adenocarcinoma, T-category was not documented,
patients suﬀered from more than one malignant tumour.
We also excluded carcinoma of the cardia (C16.0), as
these are classiﬁed either as GC or oesophageal cancer,
depending on the extent of the disease. The pTNM-stage
of all study patients was determined according to the 7th
edition of the UICC guidelines.
2.2. Statistics
Statistical analyses were carried out with SPSS 20.0
(IBM Corporation, Armonk, NY, USA). Median over-
all and tumour speciﬁc survival was determined using
the Kaplan–Meier method, and log-rank test was used
to determine signiﬁcance. For comparison, the median
survival time, its standard deviation and 95% conﬁdence
interval were indicated. For continuous variables, diﬀer-
ences between subgroups were tested using the T-test. A
value of p 6 0.05 was considered statistically signiﬁcant.
No adjustments were made.
3. Results
3.1. Study cohort and UICC
6136 patients fulﬁlled all inclusion criteria and were
operated between 2004 and 2010. 55.8% of the patients
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age ranged from 18 to 100 years (Caucasian patients:
median age 70 years; Asian patients: median age
69 years). The median overall survival time (OS) was
38.0 months, the median tumour speciﬁc survival
(TSS) time was 75.0 months. The median overall 5-year
survival rate was 42.0% (OS) and 51.7% (TSS). 1524
(24.8%) underwent total or near total gastrectomy and
4612 (75.2%) a non-total or non-near total gastrectomy.
1857 (31.0%) patients received radiotherapy. Patient
characteristics are summarised in Table 1.
In the entire study cohort, overall (OS) and
tumour speciﬁc survival (TSS) correlated signiﬁcantly
with UICC-stage grouping of GC (p < 0.001; Fig. 1A
and B; Suppl. Table 2A). No diﬀerence was found inTable 1
Clinico-pathological patients’ characteristics.
Characteristic
All patients
Age at diagnosis <70 years
P70 years
Gender Male
Female
Localisation C16.1 (Fundus)
C16.2 (Gastric c
C16.3 (Gastric a
C16.4 (Pylorus)
C16.5 (Lesser cu
C16.6 (Greater
C16.8 (Overlapp
C16.9 (Stomach
T-category T1a/b
T2
T3
T4a
T4b
Lymph nodes examined Median (Range
Positive lymph nodes Median (Range
N-category N0
N1
N2
N3a
N3b
Union internationale contre le cancer (UICC)-stage IA
IB
IIA
IIB
IIIA
IIIB
IIIC
Grading G1/G2
G3/G4
Type of surgery Non-total gastre
Total gastrectom
Radiotherapy No radiotherap
Radiotherapy
Radiotherapy uOS and TSS between men and women (data not
shown).
3.2. Ethnicity
First we studied the inﬂuence of ethnicity. The OS
and TSS diﬀered signiﬁcantly between Asian (median
OS 74.0 months; 95%CI: not calculable) and Caucasian
patients (median OS: 32.0 months; 95%CI: 29.4–34.6
months; p < 0.001; Fig. 1C; Suppl. Table 3). To explore,
whether survival diﬀerences were a result of diﬀerent
tumour stages, we correlated ethnicity with T-category,
N-category and UICC-stages. No signiﬁcant diﬀerences
were found (Table 1). In view of the signiﬁcant
survival diﬀerences between Asian and CaucasianAll Asian Caucasian
n (%) n (%) n (%)
6136 1507 (24.6) 4629 (75.4)
2997 (48.8) 770 (51.1) 2227 (48.1)
3139 (51.2) 737 (48.9) 2402 (51.9)
3424 (55.8) 830 (55.1) 2594 (56.0)
2712 (44.2) 677 (44.9) 2035 (44.0)
275 (4.5) 44 (2.9) 231 (5.0)
orpus) 770 (12.5) 179 (11.9) 591 (12.8)
ntrum) 2153 (35.1) 622 (41.3) 1531 (33.1)
348 (5.7) 76 (5.0) 272 (5.9)
rvature) 915 (14.9) 254 (16.9) 661 (14.3)
curvature) 402 (6.6) 83 (5.5) 319 (6.9)
ing regions) 564 (9.2) 114 (7.6) 450 (9.7)
NOS) 709 (11.6) 135 (9.0) 574 (12.4)
1536 (25.1) 509 (33.9) 1027 (22.2)
780 (12.7) 179 (11.9) 601 (13.0)
1998 (32.6) 420 (27.9) 1578 (34.1)
1311 (21.4) 307 (20.4) 1004 (21.7)
502 (8.2) 88 (5.9) 414 (9.0)
) 14.0 (1–90) 16.0 (1–90) 13.0 (1–90)
) 1 (0–67) 1 (0–62) 1 (0–67)
2422 (41.8) 671 (46.0) 1751 (40.4)
992 (17.1) 227 (15.5) 765 (17.6)
976 (16.8) 215 (14.7) 761 (17.6)
965 (16.7) 234 (16.0) 731 (16.9)
440 (7.6) 113 (7.7) 327 (7.5)
1123 (19.4) 397 (27.3) 726 (16.8)
568 (9.8) 157 (10.8) 411 (9.5)
826 (14.3) 169 (11.6) 657 (15.2)
695 (12.0) 162 (11.1) 533 (12.3)
700 (12.1) 134 (9.2) 566 (13.1)
1011 (17.5) 232 (15.9) 779 (18.0)
863 (14.9) 205 (14.1) 658 (15.2)
1696 (29.0) 414 (28.4) 1282 (29.1)
4152 (71.0) 1040 (71.6) 3112 (70.9)
ctomy 4612 (75.2) 1205 (80.0) 3407 (73.6)
y 1524 (24.8) 302 (20.0) 1222 (26.4)
y 4129 (67.3) 999 (66.3) 3130 (67.6)
1857 (30.3) 483 (32.1) 1374 (29.7)
nknown 150 (2.4) 25 (1.7) 125 (2.7)
Fig. 1. Kaplan–Meier survival curves: The overall and tumour speciﬁc survival of the entire study population (n = 6136 patients) according to the
stage grouping of the 7th edition of the union internationale contre le cancer (UICC)-stage grouping is shown in (A) and (B), respectively. Asian
(n = 1507) and Caucasian (n = 4629) patients show highly signiﬁcantly diﬀerent tumour speciﬁc survival curves (C). A subgroup analysis of
Caucasian patients (>15 lymph nodes resected, no radiotherapy) compared nine T-/N-combinations, each of which included >4% of the study
population (D). Kaplan–Meier curves were not signiﬁcantly diﬀerent between a variety of T-/N-combinations (see also Suppl. Table 2B).
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patients.3.3. Gastrectomy
Next we explored the inﬂuence of surgery on patient
survival in Caucasian patients. The cohort was sepa-
rated into total or near-total gastrectomy [hereafter
referred as total gastrectomy; 1222 (26.4%) patients]
and non-total or non-near total gastrectomy [hereafter
referred as non-total gastrectomy; 3407 (73.6%)
patients]. Median OS and TSS were signiﬁcantly better
for patients with non-total gastrectomy (Table 2;
p < 0.001). No diﬀerence was found between men and
women with regard to type of surgery. Interestingly,
total gastrectomy was carried out signiﬁcantly more
commonly in younger patients (mean ± SD:
64.3 ± 13.2 years; median age 65.0 years) compared
with non-total gastrectomy (mean ± SD:
67.0 ± 13.2 years; median age: 68.0 years; p < 0.001).
The signiﬁcant diﬀerence in survival may also reﬂect
diﬀerent disease stages, i.e. total gastrectomy was carried
out more commonly in more advanced cases with a
more unfavourable prognosis [24,25]. To test this
hypothesis we analysed the T-category: 76.9% of the
patients with total gastrectomy had T3/T4-tumours,compared with 59.9% of the non-total-gastrectomy
patients. Thus, patients undergoing total gastrectomy
had locally more advanced tumours.3.4. Lymph node dissection
The extent of lymph node dissection (i.e. D2-lym-
phadenectomy) has been shown to improve signiﬁcantly
patient outcome and also depends on the type of surgery
(i.e. total versus non-total gastrectomy). To test this in
the study cohort, we analysed the number of lymph
nodes resected, the number of lymph nodes with metas-
tases and the lymph node (LN)-ratio. All three variables
were signiﬁcantly diﬀerent between total and non-total
gastrectomy. Patients who underwent total gastrectomy
had signiﬁcantly more lymph nodes resected, a greater
number of lymph node metastases and also a signiﬁ-
cantly higher LN-ratio (Table 2).
The UICC currently recommends that at least 16
lymph nodes should be examined prior to classify a
GC as pN0. Next we divided the patients into two cate-
gories, i.e. 615 and >15 lymph nodes resected. Most
interestingly, the number of resected lymph nodes
(615 versus >15) did not correlate with OS or TSS in
either the entire study cohort (=any gastrectomy) or
the total gastrectomy group (Table 2). This seemingly
Table 2
Inﬂuence of type of surgery, number of lymph nodes resected and radiotherapy on overall and tumour speciﬁc patient survival in Caucas patients.
n Number of lymph
nodes examined
p-Value (T-test) Number of lymph
node metastases
p-Value (T-
test)
Lymph node ratio p-Value (T-
test)
Overall survival p-Value
(Median)
Tumour speciﬁc survival p-Value
(Median)
Mean
[SD]
Median Mean
[SD]
Median Mean [SD] Median Mean ± SD 95%
CI
Median ± SD 5%
I
Mean ± SD 95%
CI
Median ± SD 95%
CI
Any gastrectomy 4629 15.8 ± 0.2 13 4.6 ± 0.1 1 0.28 ± 0.01 0.01 42.3 ± 0.6 41.2–
43.4
32.0 ± 1.3 9.4–
4.6
– 49.0 ± 0.6 47.8–
50.1
53.0 n.c. –
Any gastrectomy; with
radiotherapy
1374 17.4 ± 0.3 15
<0.001
5.6 ± 0.2 3
<0.001
0.34 ± 0.01 0.25
<0.001
46.3 ± 1.0 44.3–
48.2
38.0 ± 2.7 2.7–
3.3 <0.001
50.5 ± 1.0 48.5–
52.6
50.0 n.c.
0.001
Any gastrectomy; no
radiotherapy
3130 15.0 ± 0.2 12 4.0 ± 0.1 0 0.25 ± 0.01 0 40.7 ± 0.7 39.3–
42.0
29.0 ± 1.6 5.9–
2.1
48.5 ± 0.7 47.1–
49.9
59.0 n.c.
Any gastrectomy, N 6 15 2514 8.3 ± 0.1 8
<0.001
2.3 ± 0.1 1
<0.001
0.27 ± 0.01 0.08
0.007
42.5 ± 0.8 41.0–
44.0
32.0 ± 1.9 8.3–
5.7 0.513
49.5 ± 0.8 47.9–
51.0
56.0 n.c.
0.570
Any gastrectomy; N > 15 1799 26.3 ± 0.3 23 7.8 ± 0.2 4 0.29 ± 0.01 0.16 43.0 ± 0.9 41.2–
44.9
33.0 ± 2.2 8.6–
7.4
48.6 ± 1.0 46.7–
50.5
49.0 n.c.
Any gastrectomy, N > 15,
with radiotherapy
634 26.5 ± 0.4 23
0.500
8.3 ± 0.3 6
0.077
0.32 ± 0.01 0.23
0.005
46.6 ± 1.5 43.7–
49.5
42.0 ± 4.5 3.2–
0.8 <0.001
51.1 ± 1.5 48.2–
54.1
59.0 n.c.
<0.001
Any gastrectomy; N > 15;
no radiotherapy
1102 26.1 ± 0.3 23 7.5 ± 0.3 2.5 0.28 ± 0.01 0.11 41.1 ± 1.2 38.7–
43.5
30.0 ± 2.4 5.2–
4.8
47.2 ± 1.2 44.7–
49.6
44.0 n.c.
Total gastrectomy 1222 20.0 ± 0.4 17 <0.001 (versus
Non-total)
7.2 ± 0.3 3 <0.001 (versus
Non-total)
0.35 ± 0.01 0.24 <0.001 (versus
Non-total)
35.0 ± 1.0 33.0–
37.0
21.0 ± 1.3 8.5–
3.5
<0.001 (versus
Non-total)
40.8 ± 1.1 38.6–
43.0
26.0 ± 2.1 21.9–
30.1
<0.001 (versus
Non-total)
Total gastrectomy; with
radiotherapy
411 20.7 ± 0.7 18
0.188
7.4 ± 0.4 5
0.460
0.37 ± 0.02 0.29
0.126
37.8 ± 1.7 34.5–
41.1
26.0 ± 2.5 1.1–
0.9 <0.001
42.2 ± 1.8 38.6–
45.7
32.0 ± 3.2 25.7–
38.3 0.003
Total gastrectomy; no
radiotherapy
777 19.5 ± 0.5 17 7.0 ± 0.4 2 0.34 ± 0.01 0.18 33.5 ± 1.3 30.9–
36.1
18.0 ± 1.4 5.2–
0.8
39.8 ± 1.4 37.0–
42.6
23.0 ± 2.9 17.4–
28.6
Total gastrectomy, N 6 15 498 9.2 ± 0.2 10
<0.001
3.1 ± 0.2 1
<0.001
0.33 ± 0.02 0.20
0.127
36.1 ± 1.6 32.9–
39.2
21.0 ± 1.5 8.1–
3.9 0.527
42.0 ± 1.7 38.6–
45.3
27.0 ± 3.9 19.3–
34.7 0.353
Total gastrectomy, N > 15 668 28.1 ± 0.5 24 10.3 ± 0.4 7 0.36 ± 0.01 0.27 34.8 ± 1.4 32.0–
37.6
21.0 ± 1.9 7.4–
4.6
40.2 ± 1.5 37.2–
43.2
26.0 ± 2.8 20.5–
31.5
Total gastrectomy, N > 15,
with radiotherapy
240 28.2 ± 0.8 24
0.884
9.9 ± 0.7 7
0.565
0.35 ± 0.02 0.27
0.711
36.0 ± 2.2 31.7–
40.3
24.0 ± 3.0 8.2–
9.8 0.031
41.5 ± 2.4 36.7–
46.2
31.0 ± 4.9 21.4–
40.6 0.023
Total gastrectomy, N > 15,
no radiotherapy
404 28.1 ± 0.6 24 10.4 ± 0.6 6.5 0.36 ± 0.02 0.25 33.9 ± 1.9 30.2–
37.5
18.0 ± 2.5 3.1–
2.9
39.0 ± 2.0 35.1–
42.9
23.0 ± 3.7 15.8–
30.2
Non-total gastrectomy 3407 14.2 ± 0.2 12 <0.001 (versus
Total)
3.6 ± 0.1 1 <0.001 (versus
Total)
0.25 ± 0.01 0.09 <0.001 (versus
Total)
45.0 ± 0.7 43.7–
46.3
38.0 ± 2.2 3.7–
2.3
<0.001 (versus
Total)
52.0 ± 0.7 50.7–
53.3
77.0 n.c. <0.001 (versus
Total)
Non-total gastrectomy; with
radiotherapy
963 15.9 ± 0.4 14
<0.001
4.8 ± 0.2 3
<0.001
0.33 ± 0.01 0.25
<0.001
49.7 ± 1.2 47.3–
52.1
50.0 ± 5.6 9.1–
0.9 <0.001
53.8 ± 1.2 51.4–
56.1
n.c. n.c.
0.007
Non-total gastrectomy; no
radiotherapy
2353 13.4 ± 0.2 11 3.0 ± 0.1 0 0.21 ± 0.01 0 43.1 ± 0.8 41.5–
44.7
34.0 ± 2.4 9.3–
8.7
51.5 ± 0.8 49.9–
53.1
77.0 n.c.
Non-total gastrectomy, N 6 15 2016 8.1 ± 0.1 8
<0.001
2.1 ± 0.1 1
<0.001
0.25 ± 0.01 0.07
0.866
44.1 ± 0.8 42.4–
45.8
36.0 ± 2.6 0.8–
1.2 0.003
51.3 ± 0.9 49.6–
53.0
71.0 n.c.
0.068
Non-total gastrectomy, N > 15 1131 25.3 ± 0.3 22 6.3 ± 0.2 3 0.25 ± 0.01 0.12 48.1 ± 1.2 45.8–
50.5
50.0 ± 6.0 8.3–
1.7
53.7 ± 1.2 51.4–
56.1
n.c. n.c.
Non-total gastrectomy, N > 15;
with radiotherapy
698 25.5 ± 0.5 23
0.472
7.3 ± 0.4 5
0.003
0.30 ± 0.01 0.21
<0.001
73.0 n.c. n.c. .c.
<0.001
56.8 ± 1.8 53.2–
60.4
n.c. n.c.
0.002
Non-total gastrectomy, N > 15;
no radiotherapy
394 25.0 ± 0.4 22 5.8 ± 0.3 1 0.22 ± 0.01 0.06 45.4 ± 1.5 42.4–
48.5
41.0 ± 6.7 7.8–
4.2
52.1 ± 1.6 49.1–
55.2
n.c. n.c.
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lymph node dissection improves patient prognosis.
3.5. Radiotherapy
1374 (29.7%) Caucasian patients received radiother-
apy. In view of the missing correlation between patient
prognosis and extent of lymph node dissection we
hypothesised that radiotherapy interferes with the eﬀects
of the surgical procedures (i.e. extent of lymph node dis-
section): radiotherapy was applied slightly more com-
monly in the total gastrectomy (33.6%) compared with
the non-total gastrectomy group (28.3%). We next
explored in further detail the inﬂuence of radiotherapy
on patient outcome.
Radiotherapy signiﬁcantly prolonged OS and TSS in
the entire cohort and in all subgroups (Table 2).
The NCCN-guidelines recommend postoperative
chemoradiation for GC based on tumour stage, nodal
status, surgical margins and the extent of lymph node
dissection [22]. To test, whether radiotherapy was
applied in more advanced disease stages, we correlated
the number of positive lymph nodes and the LN-ratio
with radiotherapy. This showed that patients receiving
radiotherapy had more lymph node metastases and aFig. 2. 5-year tumour speciﬁc survival of all possible T-/N-combinations: T
diﬀerent combinations of local tumour growth (T-category) and nodal spr
patients; 350 missing values; blue bar) and the Caucasian gastric cancer
(n = 1100; two missing values; red bar). Subsequently the diﬀerent T-/N-com
or according to the stage grouping of the UICC (B). Note the heterogeneity
subgroups.higher LN-ratio in the entire study cohort (=any
gastrectomy), in the subgroup of any gastrectomy and
>15 lymph nodes resected, the subgroups of non-total
gastrectomy and non-total gastrectomy with >15 lymph
nodes resected (Table 2). These data show that radio-
therapy was administered in more advanced stages of
GC with greater number of positive lymph nodes and
a higher LN-ratio improving OS and TSS.
3.6. Prognostic value of UICC-stage grouping
Collectively these data show that when it comes to
validating the prognostic and discriminating value of
the UICC-stage grouping, radiotherapy and extent of
lymph node dissection should be considered. Both inﬂu-
ence signiﬁcantly OS and TSS and are not applied
equally across all stage groups. Finally, we aimed to val-
idate the prognostic and discriminative value of UICC-
stage grouping in patients in whom >15 lymph nodes
were resected and who had not received any radiother-
apy. We investigated the 5-year TSS for the 25 diﬀerent
combinations of the T- and N-category (Fig. 2; Suppl.
Table 4). In general, 5-year TSS progressively declined
with increasing T-category and increasing N-category
(Fig. 2A). However, when the 25 diﬀerent T-/N-combi-he union internationale contre le cancer (UICC)-classiﬁcation enables 25
ead (N-category). These were analysed for the entire cohort (n = 5786
patients with >15 lymph nodes resected and without radiotherapy
binations were ordered according to increasing T- and N-category (A)
within the subgroups and similarity of survival rates between diﬀerent
Fig. 3. Kaplan–Meier survival curves: Stage group IIB through IIIC of the union internationale contre le cancer (UICC)-classiﬁcation combines
between four and ﬁve diﬀerent T-/N-combinations. The Kaplan–Meier analysis of these diﬀerent T-/N-combinations in Caucasian gastric cancer
patients with >15 lymph nodes resected and without radiotherapy showed that the 5-year tumour speciﬁc survival was signiﬁcantly diﬀerent in stage
groups IIIB and IIIC.
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the 7th edition, TSS was either similar between diﬀerent
stage groups (e.g. T3N1 in stage group IIB versus
T4bN2 in stage group IIIC) or signiﬁcantly diﬀerent
within a stage group (e.g. T3N2 versus T4aN1 in stage
group IIIA; Fig. 2B). To further analyse this heterogene-
ity, we carried out Kaplan Meier-analyses. These
conﬁrmed that 5-year TSS for the diﬀerent T-/N-
combinations was signiﬁcantly diﬀerent within stage
group IIIB and IIIC (Fig. 3). These signiﬁcant diﬀer-
ences were also found for the entire cohort (data not
shown). These data show that the current UICC-staging
system unites T-/N-combinations with very heteroge-
neous survival rates.
Despite the large number of patients retrieved from
the SEER-database, sixteen T-/N-combinations
enclosed <4% (range 0.2–3.5%) of the patients. In the
ﬁnal step, we aimed to identify the most prevalent T-/
N-combinations and studied the Kaplan–Meier curves
of nine T-/N-combinations, each of which included
>4% (range 4.4–18.6%) of the study population
(Fig. 1D; Suppl. Table 2B). This added up to 821
(73%) Caucasian patients, in whom >15 lymph nodes
were resected and who had not received radiotherapy.
Interestingly, Kaplan–Meier curves were not signiﬁ-
cantly diﬀerent between a variety of T-/N-combinations
(Fig. 1D; Suppl. Table 2B).4. Discussion
Our study of the SEER-database shows that a valida-
tion study for the prognostic and discriminative value of
the TNM-classiﬁcation has to consider ethnicity of the
patient population, type of surgery and oncological
treatment administered, as all signiﬁcantly aﬀect patient
outcome and hence the utility of the data obtained. In
the decade anteceding the publication of the 7th edition
of the TNM-classiﬁcation, seminal studies have set the
basis for perioperative and adjuvant chemo(radio-)ther-
apy of GC in Western countries [8,26], whilst in eastern
Asia, adjuvant chemotherapy was already standard of
care. Using the SEER-database, we identiﬁed signiﬁcant
eﬀects of radiotherapy, which improved patient survival
and is in line with previous investigations [27–29]. Sev-
eral recent validation studies of the 7th TNM-classiﬁca-
tion from eastern Asia included a substantial number of
patients who received postoperative chemotherapy
[15,17,19]. Other studies failed to specify, whether adju-
vant chemotherapy was administered, although being
highly likely (Table 3) [12,13,20]. Even studies on Wes-
tern patient populations already included 25% of
patients with adjuvant or neoadjuvant chemotherapy
[18]. The data provided by these studies are biased by
therapeutic interventions and are inadequate to validate
the prognostic utility of UICC-stage grouping, when the
Table 3
Overview of recent validation studies of the 7th edition of the TNM-classiﬁcation of gastric cancer. Recent validation studies are heterogeneous and
several include patients who received pre- or postoperative (radio-) chemotherapy.
Reference Publication
date
Patient
number
Study
period
Ethnicity (City,
Country)
Perioperative or adjuvant chemotherapy
Ahn et al. [12] 2010 9998 1986–2006 Asian (Seoul,
Korea)
No preoperative chemotherapy. However, no data on
postoperative/adjuvant chemotherapy
Kim et al. [15] 2011 464 1992–2009 Asian (Seoul,
Korea)
The systematic anticancer chemotherapy following the
gastrectomy was a standard treatment regimen
Chae et al. [13] 2011 295 2002–2006 Asian (Korea) No information provided. Note: anticancer chemotherapy
following the gastrectomy was a standard treatment regimen in
Korea and Seoul [see Kim et al. [15]]
Yoon et al. [20] 2012 1799 2001–2005 Asian (South
Korea)
Patients receiving preoperative chemotherapy were excluded;
no information on post-operative chemotherapy
Fang et al. [14] 2011 1380 1987–2006 Asian (Taiwan) Adjuvant chemotherapy or radiotherapy after curative surgery
was not performed routinely except when tumour recurrence
was diagnosed or highly suspected
Qiu et al. [17] 2011 1000 1996–2006 Asian (South
China)
50.6% of the patients received adjuvant chemotherapy
Sun et al. [19] 2012 1998 1980–2010 Asian (China) 61.4% of the patients received post-operative adjuvant
chemotherapy
Warneke et al. [21] 2011 554 1997–2009 Caucasian
(Germany)
No chemotherapy
Reim et al. [18] 2013 1767 1989–2011 Caucasian
(Germany)
6.6% of the patients received adjuvant chemotherapy
19% of the patients received neoadjuvant chemotherapy
Marrelli et al. [16] 2012 2090 1991–2005 Caucasian (Italy) No chemotherapy
McGhan et al. [43] 2012 13,547 2004–2007 Caucasian, African-
American & Other
(U.S.)
All gastric cancer patients, T- and N-staging not solely based
on pathological-anatomical investigation: 60% underwent
cancer-directed surgery, 26% received radiation therapy
Current study 2014 6136 2004–2010 Caucasian & Asian
(U.S.)
40.6% of the patients received radiotherapy
Total 41.028 1980–2011
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are not considered.
Several studies carried out on U.S. patient popula-
tions have shown that ethnicity impacts on patient sur-
vival probably reﬂecting a diﬀerence in tumour biology
of GC [30–36]. The impact of ethnicity on patient sur-
vival was also evident in our analysis and, irrespective
of treatment standards, validation studies of the
TNM-classiﬁcation carried out on Asian patients cannot
be directly compared with Caucasian patients: studies of
mixed patient populations carry the risk of providing
data, which intrinsically lead to an either over- or under-
estimation of the patient’s individual prognosis.
The UICC currently recommends that pN0 should
only be applied when >15 lymph nodes have been
resected. However, only 41.8% of the patients fulﬁlled
this criterion in our analysis. There is overwhelming evi-
dence that nodal status is strongly inﬂuenced by the
number of lymph nodes resected and examined: the N-
stage category increases proportionally with the number
of lymph nodes examined [37]. Whilst the median num-
ber of lymph nodes resected and examined increased
over time [24,38,39], it has not minimised the risk of
understaging due to low lymph node count [40,41].
Thus, TNM-stage grouping of GC carries a major risk
of understaging and is not applicable to every GC
patient, as a substantial number of elderly GC patients
may not be eligible for gastrectomy with D2-lymph nodedissection. The eﬀect of understaging might be evident in
Fig. 2. The 5-year survival rate of T1N0- and T3N0-
patients improved after patients were excluded with
<15 lymph nodes resected and was probably related to
the exclusion of patients with a false negative nodal
status.
Independently from the risk of understaging, due to
low lymph node count accurate stage grouping is unre-
alistic in almost 60% of the patients. GC is a disease
of the elderly and comorbidities may prohibit curative
gastrectomy and D2-lymph node dissection. In our anal-
ysis, the median patient age was 68 years for Caucasian
patients and total gastrectomy was carried out signiﬁ-
cantly more commonly in younger patients. Individuals
aged P65 years comprise two thirds of patients diag-
nosed with GC every year in the United States [42]
and they are less likely to receive cancer directed surgery
even for curable disease [25]. Patient age correlates
inversely with percentage of total gastrectomy, number
of lymph nodes resected and adjuvant therapy [24].
Thus, alternative systems are necessary to increase the
number of patients, in whom prognosis can be predicted
more accurately in the real clinical setting. Integration of
the lymph node ratio in the TNM-classiﬁcation was sug-
gested and may be more sensible in order to assess
patient prognosis independently form lymph node
counts. Diﬀerent systems have been published to catego-
rise lymph node ratios. However, independent valida-
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still missing [40,41].
Finally, we were unable to validate the discriminative
value of the current stage grouping of the 7th of the
UICC-classiﬁcation, after eﬀects of ethnicity, chemo-
therapy and surgery were excluded. A comparison of
the 5-year TSS of the 25 diﬀerent possible T-/N-combi-
nations showed a great heterogeneity within and
between diﬀerent stage groups (Fig. 2 & Fig. 3). This
ﬁnding is in line with previous observations made in
other Western patient populations [16,21]. We were also
unable to identify any pattern of T-/N-combinations,
which would justify either a ‘mathematical’ or tumour
biologically meaningful sorting into seven subgroups
of patients without distant metastases (M0). Currently,
the stage grouping reﬂects mainly a mathematical
model, where the addition of the values of the T- and
N-category equals the same sum total in each subgroup,
e.g. in stage IIA [(T)1 + (N)2 = 3; (T)2 + (N)1 = 3;
(T)3 + (N)0 = 3] etc. Validation of the prognostic value
of the stage grouping was further compromised in the
majority (16 out of 25) of T-/N-combinations by low
patient counts (<4% of the patient population) showing
large standard errors. In a ﬁnal step we focused on nine
T-/N-combinations, which enclosed at least 4% of the
patient population and represented 73% of the entire
population (Fig. 1C). However, again some T-/N-com-
binations falling into diﬀerent stage groups did not show
signiﬁcant diﬀerences in their survival rates. Thus, stage
grouping may need also revision with regard to the num-
ber of stage groups. Three instead of seven categories
may be more meaningful, e.g. a low risk group with
>60% 5-year survival rate (T1N0, T2N0, T3N0), an
intermediate risk group with 20–60% 5-year survival
rate (T3N1, T3N2, T3N3a, T4aN3a) and a high risk
group with <20% 5-year survival rate (T3N3b,
T4N3b). For many other T-/N-combinations there are
no suﬃcient data yet, to classify them according to
any stage grouping.
GC comprises an extremely heterogeneous disease
group, which may prohibit any meaningful stage group-
ing based solely on local tumour growth and nodal
spread. Further variables have shown to signiﬁcantly
inﬂuence patient survival such as histological phenotype
and resection status. The SEER-database does not pro-
vide any information with regard to resection status and
we did not include phenotype in our analysis, as this
necessitates a centralised surgical pathological re-assess-
ment of all cases.
In summary, our retrospective analysis of the SEER-
database does not validate the prognostic and discrimi-
nating value of stage grouping of the 7th edition of the
UICC-stage grouping. A revision should be considered
also including lymph node ratios in order to prognosti-
cate patient’s survival for those patients, in whom 615
lymph nodes are resected, i.e. more than half of theGC patients. Furthermore, novel prognostic biomarkers
are urgently needed, which reliably distinguish diﬀerent
patient groups independent from tumour type.
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